NO20070640L - Forbedrede aprotininvananter - Google Patents

Forbedrede aprotininvananter

Info

Publication number
NO20070640L
NO20070640L NO20070640A NO20070640A NO20070640L NO 20070640 L NO20070640 L NO 20070640L NO 20070640 A NO20070640 A NO 20070640A NO 20070640 A NO20070640 A NO 20070640A NO 20070640 L NO20070640 L NO 20070640L
Authority
NO
Norway
Prior art keywords
improved
proteins
field
aprotinin
additives
Prior art date
Application number
NO20070640A
Other languages
English (en)
Inventor
Kevin Lumb
Stanley Horton
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20070640L publication Critical patent/NO20070640L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til feltet av proteiner som inhiberer serinproteaseaktivitet. Oppfinnelsen er også relatert til feltet av nukleinsyrekonstruksjoner, vektorer og vertsceller for å produsere serinproteaseinhiberende proteiner, farmasøytiske sammensetninger som inneholder slike proteiner og fremgangsmåter for deres anvendelse.
NO20070640A 2004-07-13 2007-02-05 Forbedrede aprotininvananter NO20070640L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58765504P 2004-07-13 2004-07-13
PCT/US2005/024951 WO2006017355A2 (en) 2004-07-13 2005-07-13 Improved aprotinin variants

Publications (1)

Publication Number Publication Date
NO20070640L true NO20070640L (no) 2007-04-11

Family

ID=35839810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070640A NO20070640L (no) 2004-07-13 2007-02-05 Forbedrede aprotininvananter

Country Status (15)

Country Link
US (1) US20090005297A1 (no)
EP (1) EP1771464A4 (no)
JP (1) JP2008506391A (no)
KR (1) KR20070041749A (no)
CN (1) CN101014611A (no)
AU (1) AU2005271708A1 (no)
BR (1) BRPI0513267A (no)
CA (1) CA2573368A1 (no)
EC (1) ECSP077240A (no)
IL (1) IL180370A0 (no)
MA (1) MA28779B1 (no)
MX (1) MX2007000473A (no)
NO (1) NO20070640L (no)
RU (1) RU2007105137A (no)
WO (1) WO2006017355A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
CN101412995B (zh) * 2007-10-17 2011-04-06 江苏正大天晴药业股份有限公司 聚乙二醇修饰的抑肽酶及其制备方法
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
WO2010088547A1 (en) * 2009-01-29 2010-08-05 Bayer Healthcare Llc Assays for detecting pegylated blood coagulation factors
DE102011013326A1 (de) 2011-03-08 2012-09-13 Solution Shop Ag Neue Fibrinolyse-Inhibitoren und deren mdizinische Verwendung
ES2800426T3 (es) * 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
US9605057B1 (en) * 2013-06-17 2017-03-28 Board Of Regents Of The University Of Texas System Endotrophin neutralization and use thereof
EP3387012A4 (en) * 2015-12-10 2019-05-15 The National Institute for Biotechnology in the Negev Ltd. VARIANTS OF THE AMYLOID BETA PROTEIN PROVIDER INHIBITOR DOMAIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015605A2 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1771464A2 (en) 2007-04-11
MA28779B1 (fr) 2007-08-01
BRPI0513267A (pt) 2008-05-06
ECSP077240A (es) 2007-03-29
CN101014611A (zh) 2007-08-08
WO2006017355A3 (en) 2006-12-14
AU2005271708A1 (en) 2006-02-16
WO2006017355A2 (en) 2006-02-16
US20090005297A1 (en) 2009-01-01
KR20070041749A (ko) 2007-04-19
EP1771464A4 (en) 2008-09-03
MX2007000473A (es) 2007-03-29
IL180370A0 (en) 2007-06-03
RU2007105137A (ru) 2008-08-20
CA2573368A1 (en) 2006-02-16
JP2008506391A (ja) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20070640L (no) Forbedrede aprotininvananter
NO20080067L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse
NO20070866L (no) Antivirale forbindelser.
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
SE0201980D0 (sv) Novel compounds
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
MX2010001481A (es) Proteasas fungales acidas.
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application